DR. CARLOS A. OSMON, MD

AUSTELL, GA

Research Active
Internal Medicine - Hematology & Oncology NPI registered 21+ years 1 publication 1999 – 1999 NPI: 1225033640
Internal Medicine - Hematology & Oncology
Antineoplastic AgentsColorectal NeoplasmsCombined Modality TherapyFluorouracilLeucovorinRecombinant ProteinsInterferon alpha-2Interferon-alphaAntimetabolites, AntineoplasticAntidotes

Practice Location

1700 HOSPITAL SOUTH DR STE 300
AUSTELL, GA 30106-8116

Phone: (770) 944-2830

What does CARLOS OSMON research?

Dr. Osmon studies advanced colorectal cancer, a serious type of cancer that affects the colon and rectum. His research specifically looks at different combinations of chemotherapy and other treatments to find options that may help patients live longer and have better quality of life. Recently, he researched a combination treatment that includes 5-fluorouracil, folinic acid, and recombinant alpha-2a-interferon, aiming to determine the best ways to manage this challenging disease.

Key findings

  • In his Phase II trial, the combination treatment had an overall response rate of 29%.
  • Patients treated with the combination survived a median of 15.5 months after starting the treatment.
  • The combination therapy resulted in more side effects but was not more effective than using just 5-fluorouracil with one other drug.

Frequently asked questions

Does Dr. Osmon study colorectal cancer?
Yes, Dr. Osmon specializes in research on advanced colorectal cancer.
What treatments has Dr. Osmon researched?
He has researched combinations including 5-fluorouracil, folinic acid, and recombinant alpha-2a-interferon.
Is Dr. Osmon's work relevant to patients with advanced cancer?
Yes, his research aims to find effective treatment options that can help improve survival and quality of life for patients with advanced colorectal cancer.

Publications in plain English

Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer.

1999

Anti-cancer drugs

Ravandi F, Rytting ME, Osmon C, Braud EL, Roach RW +4 more

Plain English
Researchers studied a treatment combining 5-fluorouracil, folinic acid, and a drug called recombinant alpha-2a-interferon in patients with advanced colorectal cancer. They found that this combination had an overall response rate of 29%, with patients surviving a median of 15.5 months after starting treatment. However, the combination caused more side effects and was no more effective than using 5-fluorouracil with just one of the other drugs. Who this helps: This information helps doctors in their treatment planning for patients with advanced colorectal cancer.

PubMed

Frequent Co-Authors

F Ravandi M E Rytting E L Braud R W Roach K Edwards R Winn J L Abbruzzese R Pazdur

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.